Effectiveness and safety of VISULAS® green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
Open Access
- 26 December 2022
- journal article
- research article
- Published by Springer Nature in International Ophthalmology
- Vol. 43 (7) , 2215-2224
Abstract
Purpose To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS® green laser in patients with primary open-angle glaucoma (POAG). Methods This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS® green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. Results Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. Conclusions SLT performed with the VISULAS® green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies.Keywords
Funding Information
- Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
This publication has 24 references indexed in Scilit:
- Complications of selective laser trabeculoplasty: a reviewClinical Ophthalmology, 2016
- Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucomaSurvey of Ophthalmology, 2015
- Selective Laser Trabeculoplasty Versus Medical Therapy as Initial Treatment of GlaucomaJournal of Glaucoma, 2012
- SLT and Adjunctive Medical TherapyJournal of Glaucoma, 2011
- Selective Laser TrabeculoplastyJournal of Glaucoma, 2008
- Reduction of Intraocular Pressure and Glaucoma ProgressionArchives of Ophthalmology (1950), 2002
- The Ocular Hypertension Treatment StudyArchives of Ophthalmology (1950), 2002
- Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty)Ophthalmology, 1998
- Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressuresAmerican Journal of Ophthalmology, 1998
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934